he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信息论地址
- 2022-05-03JNER:采用多关节手臂外骨骼对中风后上肢运动进行运动学评估的临床验证
- 2022-05-02哪些抗菌药物可其会癫痫?
- 2022-04-25卒中后高血压首选用药有哪些?解答卒中后高血压的4大问题
- 2022-04-212013年国际抗癫痫总会抗癫痫药使用指南
- 2022-02-28罕见的癫痫病症状有哪些
- 2022-02-28千万别忽视小孩癫痫病症状
- 卒中后高血压首选用药有哪些?解答卒中后高血压的4大问题
- 2013年国际抗癫痫总会抗癫痫药使用指南
- 吡仑帕奈辅助用药可改善部分发作型癫痫患者的副作用
- A&R: Semaphorin3B 在血清诱导的关节炎模型中发挥核心作用,减少类风湿性关节炎患者
- FDA批准Aptiom用于治疗患者癫痫发作
- 浙江省首次引进数字乳腺断层融合摄影,检出率提高30%以上
- 癫痫猝死:凶手是谁?
- 预测癫痫患者再入院风险
- 低剂量阿司匹林可预防结直肠癌
- 女性,腹胀2个多月,发现腹盆腔肿块,请诊断!
- 私密┃月经结束了。内衣上这些棕色的东西是什么?
- J Allergy Clin Immunol:IgE对鼻息肉有影响吗?
- Eur J Cancer:单纯前哨淋巴结切除术有望取代早期宫颈癌的盆腔淋巴结清洁!
- 子宫肌瘤出血的原因是什么?
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- JAAD:介绍滤泡性湿疹
- 男性乳腺增生 为什么男性乳腺增生?
- 你知道吗?快看护理知识!
- 每四个女人就有一个子宫肌瘤。这个肿瘤有多可怕?
- 乳腺癌的早期症状
- 这件事对女性子宫危害很大,但很多女性不了解,认为很简单
- BMC Urol:晚期癌症患者服用阿帕鲁胺后出现皮疹需要特殊治疗吗?
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- A&R:洛西汀对髋关节或膝关节骨性关节炎慢性疼痛患者没有附加值
- 第一次同房失败,怎么治疗?
- UCB的Vimpat癫痫新适应症在美国获批
- Stroke:家族性和散发性颅内动脉瘤破裂的风险比较
- Cell J:对比研究揭示了子宫内膜异位症的另一种可能机制
- 月经期间要注意 有些药物和食物不能食用
- 女人过早对夫妻不利
- 20110630cctv10健康之路:张瑾解读乳腺癌防治方法
- 抗病毒方案修订对抗病毒结果和费用的影响
- 最新治疗法癫痫病方法有什么
- 大咖直播—6 大公益援助详解:国际癫痫关爱日,患者最高可获 10 万元切除术费用减免
- 羊角风的最新治疗方式你有过了解吗
- UCB的Vimpat癫痫新用药在美国获批
- 癫痫病人大脑为什么不会放电 尽早用药可以控制症状
- 癫痫病患者大发作的致病
- 阿尔茨海默病或是人类特有疾病,同神经纤维及神经环路活性异常相关
- 上海率先探索异地就医门诊费直接结算
- 小儿良性癫痫病有什么病因
- 孕妇能吃汽水吗 食用汽水过度危害大(2)
- AAN/AES发布新版首次非诱发连续性癫痫发作诊疗指南
- 治疗癫痫病食品要怎么治疗好啊